Tempus AI Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Eric Lefkofsky
Chief executive officer
US$41.5m
Total compensation
| CEO salary percentage | 1.89% |
| CEO tenure | no data |
| CEO ownership | 23.2% |
| Management average tenure | 4.7yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Seeking Alpha • Jul 13
Tempus AI: The Market Is Betting On An Inflection I Can't Yet See
Summary Tempus AI is now trading near my October DCF-derived fair value of $62.55, following a sharp growth deceleration and reduced expectations. TEM’s 2026 guidance implies 25% revenue growth, but persistent cash burn and negative Q1 adjusted EBITDA raise concerns about near-term profitability. The Data business remains the key long-term driver, with 40.5% Y/Y revenue growth and 73.1% non-GAAP margins, but SG&A remains high. I maintain a cautious Hold rating, as the current valuation still demands sustained 20%+ CAGR and a clear inflection to cash generation. Read the full article on Seeking Alpha
Narrative Update • Jul 11
TEM: Early Healthcare AI Theme And Profit Concerns May Restrain Upside
Tempus AI's analyst fair value estimate has shifted from about $58.00 to $37.83 as analysts factor in slightly softer revenue growth, more modest long term profit margin expectations, and a lower future P/E multiple, while still acknowledging the company's differentiated oncology data platform and early position in healthcare AI. Analyst Commentary Recent research on Tempus AI points to a split view.
Narrative Update • Jun 27
TEM: FDA Approvals And Data Platform Progress Will Drive Future Upside
The analyst fair value estimate for Tempus AI has shifted from about $105.00 to roughly $95.45, as analysts recalibrate assumptions on revenue growth, profit margins, discount rate, and future P/E in light of recent mixed research that praises the company's differentiated data platform while questioning the clarity and timing of long term monetization. Analyst Commentary Recent Street research on Tempus AI points to a mixed but active debate, with several bullish analysts highlighting strengths in the company’s data platform and potential for execution on its long term roadmap.Analysis Article • Jun 19
Tempus AI (TEM) Stock Could Be 22.9% Undervalued After ECG AF Validation
Tempus AI (TEM) is back in focus after publishing a multi site validation of its FDA cleared ECG AF software, which predicts one year atrial fibrillation or flutter risk in older adults without prior AF. See our latest analysis for Tempus AI. Tempus AI’s shares have picked up momentum recently, with a 1 month share price return of 10.81% and a 7 day gain of 6.32%. However, the year to date share price return is still down 18.47% and the 1 year total shareholder return has declined 25.57%...
Narrative Update • Jun 13
TEM: FDA Progress And Data Platforms Will Drive Future Oncology Demand
Tempus AI's analyst price targets have shifted lower to around $66.53, reflecting a mix of downward revisions and more cautious views on long term monetization from several firms, even as others acknowledge the company's differentiated data offering. Analyst Commentary Recent research paints a mixed picture around Tempus AI, with views split on how quickly the company can translate its differentiated data assets into predictable cash flows and what that should mean for valuation.
New Narrative • Jun 09
An Overlooked AI Play That’s Quietly Building a Healthcare Data Empire
Tempus AI isn't simply an AI software business (not another ChatBot). It's building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect.Narrative Update • May 30
TEM: FDA Approvals And Partnerships Will Support Future Oncology Data Demand
Narrative Update The average analyst price target for Tempus AI has moved lower by several dollars to reflect a mix of reduced targets from H.C. Wainwright, BTIG, Baird, Guggenheim, and Morgan Stanley, partially offset by modest upward revisions and an upgrade from TD Cowen and TD Securities. Analysts are incorporating recent results, updated models, and ongoing partnership activity into their assessments.Narrative Update • May 13
TEM: Data Partnerships And Backlog Will Support Future Oncology Data Upside
Tempus AI's analyst price target is now $67.20, down from $72.40, as analysts adjust their models to reflect more moderate revenue growth assumptions and mixed recent price target revisions across the Street. Analyst Commentary Recent research on Tempus AI shows a mix of optimism and caution as analysts update their models, adjust price targets, and refine views following Q4 results and new coverage initiations.Narrative Update • Apr 28
TEM: Data Partnerships And Backlog Will Support Future Oncology Data Monetization
Analysts have slightly reduced the blended price target on Tempus AI to $72.40. This reflects updated models around revenue growth, profit margins and P/E assumptions after a mix of target cuts and increases across recent research, including responses to Q4 results and ongoing partnership momentum.Narrative Update • Apr 13
TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Leadership
Narrative Update on Tempus AI The updated analyst price target for Tempus AI moves to $72.73 from $77.93, as analysts factor in slightly higher discount rates and a lower future P/E multiple. They still point to ongoing partnerships and data backlog as key supports for the long term story.Narrative Update • Mar 26
TEM: Data Partnerships And Backlog Will Drive Future Precision Oncology Execution
Analysts report a modestly adjusted fair value estimate of $77.93 per share for Tempus AI, reflecting mixed price target revisions that weigh the impact of new partnerships and data backlog strength against updated post Q4 models and views on visibility in parts of the business. Analyst Commentary Recent Street research on Tempus AI reflects a split view, with some focusing on growth potential in precision medicine and data, and others emphasizing execution risks and visibility in parts of the business.Narrative Update • Mar 11
TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Upside
Our updated view trims Tempus AI's implied fair value from about $86.71 to $77.93 per share, reflecting analysts' mixed price target revisions after Q4. Some highlight expanding pharma and academic partnerships and a large data backlog, while others factor in model updates, valuation resets, and questions around data upside and Ambry.New Narrative • Mar 04
Heavy AI Infrastructure And Rising Costs Will Pressure Data Economics Yet Eventually Support Upside
Catalysts About Tempus AI Tempus AI provides AI driven molecular diagnostics and data products to support clinical decision making and drug development. What are the underlying business or industry changes driving this perspective?Narrative Update • Feb 24
TEM: Precision Oncology And AI Biomarkers Will Support Future Upside Potential
Narrative update on Tempus AI The updated analyst price target for Tempus AI has edged down by about $1 to reflect slightly lower fair value and profit margin assumptions, even as analysts highlight the company's role in precision oncology diagnostics and AI-enabled healthcare data services as a key factor in its long term revenue growth outlook. Analyst Commentary Recent research coverage on Tempus AI highlights both enthusiasm for its role in precision oncology and AI driven healthcare data, and a set of execution and valuation questions that investors are watching closely.New Narrative • Feb 18
Genomics And AI Data Licensing Will Transform Long Term Oncology Outcomes
Catalysts About Tempus AI Tempus AI operates a genomics and data platform focused on Oncology and related clinical insights. What are the underlying business or industry changes driving this perspective?Narrative Update • Feb 10
TEM: AI Biomarker Advancements In Oncology Will Drive Future Returns
Analysts have nudged their price target on Tempus AI higher to about US$87.92, citing slightly stronger modeled revenue growth, profit margins, and a marginally lower future P/E assumption in their updated forecasts. What's in the News Tempus reported new clinical validation data for its Immune Profile Score test, indicating that the algorithmic biomarker more accurately predicts outcomes for patients receiving immune checkpoint inhibitors than several conventional biomarkers across multiple metastatic solid tumor cohorts.Narrative Update • Jan 26
TEM: Oncology Data Collaborations And AI Pathology Will Drive Future Returns
Analysts have kept their fair value estimate for Tempus AI steady at about US$87.92 per share, with only very small tweaks to inputs like discount rate, revenue growth, profit margins and future P/E assumptions supporting an unchanged overall target. What's in the News Tempus AI launched Paige Predict, a suite of AI pathology tools that analyze H&E whole slide images to help predict the likelihood of 123 biomarkers and oncogenic pathways across 16 cancer types, with results delivered alongside clinical reports to physicians (Product-Related Announcements).Narrative Update • Jan 12
TEM: Oncology Data Collaborations Will Drive Future Returns Despite Slightly Higher Risk
Analysts have trimmed their fair value estimate for Tempus AI by about US$1.00, reflecting slightly higher discount rate assumptions as well as marginally adjusted revenue growth, profit margin, and future P/E inputs. What's in the News Tempus AI plans to present ten research abstracts at the 2025 San Antonio Breast Cancer Symposium, focusing on multimodal real world data, risk stratification for CDK4/6 inhibitor plus endocrine therapy, and tumor microenvironment signatures in hormone receptor positive, HER2 negative metastatic breast cancer (Key Developments).Narrative Update • Dec 25
TEM: Future Oncology Data Partnerships Will Drive Profits Despite Modestly Higher Risk
Analysts have modestly reduced their price target on Tempus AI by approximately 3 dollars, reflecting slightly higher perceived risk and marginally slower long term growth expectations, partly offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Tempus AI will present ten research abstracts at the 2025 San Antonio Breast Cancer Symposium, showcasing multimodal real world data approaches to better stratify metastatic breast cancer patients and identify responders to CDK4/6 inhibitors (Key Developments).Narrative Update • Dec 11
TEM: Future Profit Margins Will Expand As Federal Oncology Program Catalysts Mature
Narrative Update on Tempus AI Analyst Price Target Analysts have slightly raised their price target on Tempus AI to approximately 91 dollars and 42 cents from 91 dollars, citing a marginally lower perceived risk profile and stable long term growth and profitability assumptions. What's in the News Tempus received FDA 510(k) clearance for its RNA based xR IVD sequencing assay, expanding its toolkit for drug development partners and strengthening its position as a comprehensive precision oncology platform (FDA filing).Narrative Update • Nov 26
TEM: Future Profit Margins Will Expand With AI-Powered Clinical Partnerships
Analysts have revised Tempus AI's price target upwards from $87.17 to $91.00, citing improved profit margin projections and a significantly lower anticipated future price-to-earnings ratio. What's in the News Tempus AI and the Institute for Follicular Lymphoma Innovation (IFLI) launched their first collaborative research study with a non-profit foundation to create a comprehensive, multi-omic dataset for follicular lymphoma.Narrative Update • Nov 09
TEM: Revenue Will Accelerate With New Real-World Data Partnership
Analysts have raised their price target for Tempus AI from $82.50 to $87.17, citing shifts in expected growth and profitability as supporting factors for the updated valuation. What's in the News Tempus AI announced six new abstracts accepted for presentation at the SITC Annual Meeting 2025, highlighting advances in multi-omic algorithms and biomarkers for rare and advanced cancers (Product-Related Announcements).Narrative Update • Oct 26
Advances In Precision Medicine And AI Will Reshape Cancer Care Futures
Analysts have raised their price target for Tempus AI from $77.55 to $82.50, citing stronger confidence in revenue growth and profitability projections. What's in the News Tempus AI and Whitehawk Therapeutics announced a multi-year collaboration to use Tempus' real-world dataset to advance biomarker-driven research and enhance oncology clinical trial design.Narrative Update • Oct 12
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI's fair value estimate has been raised by analysts from $74.82 to $77.55 per share. This reflects optimism about improved revenue growth and updated market outlooks.Analysis Article • Oct 09
After Leaping 29% Tempus AI, Inc. (NASDAQ:TEM) Shares Are Not Flying Under The Radar
Despite an already strong run, Tempus AI, Inc. ( NASDAQ:TEM ) shares have been powering on, with a gain of 29% in the...Narrative Update • Sep 28
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI’s valuation has become more expensive with a higher forward P/E and declining net profit margin, leading to only a marginal increase in the consensus analyst price target to $74.82. What's in the News Tempus AI received FDA 510(k) clearance for its RNA-based Tempus xR IVD device and updated Tempus Pixel cardiac imaging platform, expanding its diagnostics and AI imaging capabilities.Narrative Update • Sep 13
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI’s consensus future P/E and discount rate held steady with minimal movement, supporting only a slight upward revision in fair value from $72.73 to $73.45. What's in the News Tempus AI received FDA 510(k) clearance for its updated Tempus Pixel, an AI-powered cardiac imaging platform, which now enables generation of T1 and T2 inline maps for enhanced cardiac MR image analysis, supporting more precise and efficient diagnostics.Narrative Update • Aug 27
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI's slightly higher consensus price target reflects a significant increase in its future P/E ratio despite a decline in net profit margin, resulting in a new fair value estimate of $71. What's in the News Tempus AI filed a $500 million follow-on equity offering of Class A Common Stock via an at-the-market transaction and raised its full-year 2025 revenue guidance to approximately $1.26 billion, representing ~82% annual growth.Analysis Article • Aug 15
Tempus AI, Inc. (NASDAQ:TEM) Looks Just Right With A 28% Price Jump
Tempus AI, Inc. ( NASDAQ:TEM ) shareholders would be excited to see that the share price has had a great month, posting...New Narrative • Jun 15
AstraZeneca And Pathos Partnership Will Expand Precision Medicine
Pharma partnerships and the shift toward AI-driven precision medicine are fueling strong, high-margin revenue growth and expanding Tempus' competitive opportunities.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$303m |
| Dec 31 2025 | US$41m | US$783k | -US$245m |
| Sep 30 2025 | n/a | n/a | -US$203m |
| Jun 30 2025 | n/a | n/a | -US$199m |
| Mar 31 2025 | n/a | n/a | -US$720m |
| Dec 31 2024 | US$29m | n/a | -US$745m |
| Sep 30 2024 | n/a | n/a | -US$801m |
| Jun 30 2024 | n/a | n/a | -US$790m |
| Mar 31 2024 | n/a | n/a | -US$293m |
| Dec 31 2023 | US$2k | n/a | -US$254m |
| Sep 30 2023 | n/a | n/a | -US$276m |
| Dec 31 2022 | US$2k | n/a | -US$334m |
Compensation vs Market: Eric's total compensation ($USD41.50M) is above average for companies of similar size in the US market ($USD14.57M).
Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.
CEO
Eric Lefkofsky (56 yo)
no data
Tenure
US$41,495,833
Compensation
Mr. Eric P. Lefkofsky, J.D., is Co-Founder & Chairman of Pathos AI, Inc. Mr. Lefkofsky was Executive Director of Pathos AI, Inc. Mr. Eric P. Lefkofsky is Co-Founder of Groupon, Inc. from November 2023. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | US$41.50m | 23.22% $ 2.4b | |
| Chief Financial Officer | 5.3yrs | US$6.36m | 0.0049% $ 517.3k | |
| Executive VP and Chief Administrative & Legal Officer | 6.1yrs | US$4.55m | 0.014% $ 1.5m | |
| General Counsel | less than a year | US$6.58m | 0.011% $ 1.2m | |
| Chief Executive Officer of Data & Apps | less than a year | US$11.60m | 0.40% $ 42.6m | |
| Chief Accounting Officer | no data | no data | 0.011% $ 1.1m | |
| Chief Technology Officer | no data | no data | no data | |
| Chief Scientific Officer | 3.8yrs | no data | no data | |
| Vice President of Investor Relations & Competitive Intelligence | no data | no data | no data | |
| Senior VP & Head of Corporate Development | 5.5yrs | no data | no data | |
| Chief People Officer | 4.2yrs | no data | no data | |
| Senior Vice President of External Affairs | 6.8yrs | no data | no data |
4.7yrs
Average Tenure
48yo
Average Age
Experienced Management: TEM's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | US$41.50m | 23.22% $ 2.4b | |
| Independent Director | 8.8yrs | US$199.67k | 0.059% $ 6.3m | |
| Independent Director | 7.5yrs | US$187.17k | 0.041% $ 4.3m | |
| Independent Director | 2.4yrs | US$187.25k | 0.0060% $ 632.1k | |
| Independent Director | 7.5yrs | US$187.17k | 0.012% $ 1.2m | |
| Independent Director | 6.8yrs | US$187.17k | 0.0082% $ 868.1k | |
| Independent Director | 5.3yrs | US$188.18k | 0.0066% $ 699.5k | |
| Independent Director | 5.8yrs | US$187.17k | 0.0089% $ 941.8k | |
| Member of Advisory Board | 1.3yrs | no data | no data | |
| Independent Director | 5.3yrs | US$187.17k | 0.013% $ 1.4m | |
| Advisory Board Member | 1.3yrs | no data | no data | |
| Member of Advisory Board | 1.3yrs | no data | no data |
5.3yrs
Average Tenure
62yo
Average Age
Experienced Board: TEM's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/15 03:58 |
| End of Day Share Price | 2026/07/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tempus AI, Inc. is covered by 24 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |